CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.08B, above the global median of $1.15B
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
16.33BHKD2.08B · vs all stocks (USD)
Revenue (TTM)
374.08MHKD47.68M · vs all stocks (USD)
Profit Margin
-69.32%52-Week Change
-11.90%vs all stocks
Market Capitalization
16.33BHKD2.08B · vs all stocks (USD)
Enterprise Value
13.13BHKD1.67B · vs all stocks (USD)
Price to Sales (TTM)
35.63xPrice to Book (MRQ)
273.17xEnterprise to Revenue
35.10xEnterprise to EBITDA
-77.87xGross Margin
91.08%Profit Margin
-69.32%Operating Margin
-42.65%Return on Assets (TTM)
-16.04%Return on Equity (TTM)
-176.49%Revenue (TTM)
374.08MHKD47.68M · vs all stocks (USD)
Revenue per Share (TTM)
0.8990HKDUpdated Jul 15, 2026Quarterly Revenue Growth
959.80%Gross Profit (TTM)
251.72MHKD32.08M · vs all stocks (USD)
EBITDA (TTM)
-168.60MHKD-21.49M · vs all stocks (USD)
Net Income (TTM)
-259.31MHKD-33.05M · vs all stocks (USD)
Operating Cash Flow (TTM)
-142.66MHKD-18.18M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-258.72MHKD-32.98M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Jul 15, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
259.61MCNYFY2024 · Dec 31, 2024Cost of Goods Sold
108.16MCNYFY2024 · Dec 31, 2024Gross Profit
151.46MCNYFY2024 · Dec 31, 2024Operating Income
-229.09MCNY-33.96M · vs all stocks (USD)
Pre-tax Income
-258.72MCNYFY2024 · Dec 31, 2024Income Tax Expense
0.00CNYFY2024 · Dec 31, 2024Net Income
-258.72MCNYFY2024 · Dec 31, 2024EBIT
-241.00MCNYFY2024 · Dec 31, 2024EBITDA (Income Statement)
-172.38MCNYFY2024 · Dec 31, 2024Research & Development
205.57MCNYFY2024 · Dec 31, 2024Selling, General & Administrative
122.98MCNYFY2024 · Dec 31, 2024Non-operating Interest Income
474.00KCNYFY2024 · Dec 31, 2024Non-operating Interest Expense
17.71MCNYFY2024 · Dec 31, 2024EPS (Basic)
-0.6576CNYFY2024 · Dec 31, 2024EPS (Diluted)
-0.6576CNYFY2024 · Dec 31, 2024Basic Shares Outstanding
393.44MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
393.44MSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
-258.72MCNYFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00CNYFY2024 · Dec 31, 2024Operating Cash Flow
-390.15MCNYFY2024 · Dec 31, 2024Free Cash Flow
-589.23MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
132.19MCNYFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-258.72MCNYFY2024 · Dec 31, 2024Stock-based Compensation
41.67MCNYFY2024 · Dec 31, 2024Other Non-cash Items
15.47MCNYFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-225.95MCNYFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
37.38MCNYFY2024 · Dec 31, 2024Capital Expenditures
-199.07MCNYFY2024 · Dec 31, 2024Net Intangibles (CF)
-594.00KCNYFY2024 · Dec 31, 2024Purchase of Investments
-120.00MCNYFY2024 · Dec 31, 2024Sale of Investments
152.50MCNYFY2024 · Dec 31, 2024Other Investing Activity
14.02MCNYFY2024 · Dec 31, 2024Net Investing Cash Flow
-152.55MCNYFY2024 · Dec 31, 2024Long-term Debt Issuance
793.03MCNYFY2024 · Dec 31, 2024Long-term Debt Payments
-336.19MCNYFY2024 · Dec 31, 2024Net Financing Cash Flow
456.85MCNYFY2024 · Dec 31, 2024Shares Outstanding
393.44MSharesUpdated Jul 15, 2026Float Shares
125.93MSharesUpdated Jul 15, 2026% Held by Insiders
74.94%vs all stocks
% Held by Institutions
12.89%vs all stocks
Total Cash (MRQ)
125.28MHKD15.97M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3010HKDUpdated Jul 15, 2026Total Debt (MRQ)
1.06BHKD134.97M · vs all stocks (USD)
Total Debt to Equity (MRQ)
27.23xCurrent Ratio (MRQ)
0.4410xBook Value per Share (MRQ)
0.1073HKDUpdated Jul 15, 2026Total Assets
1.61BCNY239.07M · vs all stocks (USD)
Total Current Assets
495.54MCNYFY2024 · Dec 31, 2024Total Liabilities
1.47BCNYFY2024 · Dec 31, 2024Total Non-current Assets
1.12BCNYFY2024 · Dec 31, 2024Total Non-current Liabilities
557.57MCNYFY2024 · Dec 31, 2024Total Current Liabilities
908.68MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents
132.19MCNYFY2024 · Dec 31, 2024Accounts Receivable
284.90MCNYFY2024 · Dec 31, 2024Inventory
57.81MCNYFY2024 · Dec 31, 2024Accounts Payable
441.62MCNYFY2024 · Dec 31, 2024Short-term Debt
354.67MCNYFY2024 · Dec 31, 2024Long-term Debt
504.14MCNYFY2024 · Dec 31, 2024Common Stock (Book)
360.00MCNYFY2024 · Dec 31, 2024Retained Earnings
-969.08MCNYFY2024 · Dec 31, 2024Total Shareholders' Equity
146.59MCNY21.73M · vs all stocks (USD)
52-Week Low
28.88HKDUpdated Jul 15, 202652-Week High
73.00HKDUpdated Jul 15, 202652-Week Change
-11.90%vs all stocks
50-Day MA
29.32HKDUpdated Jul 15, 2026200-Day MA
39.48HKDUpdated Jul 15, 2026Avg 10-Day Volume
56.09KSharesUpdated Jul 15, 2026Avg 30-Day Volume
4.23KSharesUpdated Jul 15, 2026Diluted EPS (TTM)
-0.6600HKDUpdated Jul 15, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Where is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.08B, above the global median of $1.15BNotable
Market cap (USD): 2,081,150,042.534Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aurinia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Moura Dubeux Engenharia S.A.
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthReceivables Heavy and Growing
Krishana Phoschem Ltd.
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthReceivables Heavy and Growing
Coforge Limited
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthReceivables Heavy and Growing